Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
| Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke |
| Pubbl/distr/stampa | Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 |
| Descrizione fisica | 1 online resource (527 p.) |
| Disciplina | 615.19 |
| Collana | Methods and Principles in Medicinal Chemistry |
| Soggetto topico |
Drug development
Drugs - Design Ligands (Biochemistry) Drug Discovery LIgands |
| ISBN |
3-527-68362-3
3-527-68360-7 3-527-68361-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Fragment-based Drug Discovery: Lessons and Outlook; Contents; Contributors; Preface; A Personal Foreword; Part I: The Concept of Fragment-based Drug Discovery; 1. The Role of Fragment-based Discovery in Lead Finding; 1.1 Introduction; 1.2 What is FBLD?; 1.3 FBLD: Current Practice; 1.3.1 Using Fragments: Conventional Targets; 1.3.2 Using Fragments: Unconventional Targets; 1.4 What do Fragments Bring to Lead Discovery?; 1.5 How did We Get Here?; 1.5.1 Evolution of the Early Ideas and History; 1.5.2 What has Changed Since the First Book was Published in 2006?
1.6 Evolution of the Methods and Their Application Since 20051.6.1 Developments in Fragment Libraries; 1.6.2 Fragment Hit Rate and Druggability; 1.6.3 Developments in Fragment Screening; 1.6.4 Ways of Evolving Fragments; 1.6.5 Integrating Fragments Alongside Other Lead-Finding Strategies; 1.6.6 Fragments Can be Selective; 1.6.7 Fragment Binding Modes; 1.6.8 Fragments, Chemical Space, and Novelty; 1.7 Current Application and Impact; 1.8 Future Opportunities; References; 2. Selecting the Right Targets for Fragment-Based Drug Discovery; 2.1 Introduction 2.2 Properties of Targets and Binding Sites2.3 Assessing Druggability; 2.4 Properties of Ligands and Drugs; 2.5 Case Studies; 2.5.1 Case Study 1: Inhibitors of Apoptosis Proteins (IAPs); 2.5.2 Case Study 2: HCV-NS3; 2.5.3 Case Study 3: PKM2; 2.5.4 Case Study 4: Soluble Adenylate Cyclase; 2.6 Conclusions; References; 3. Enumeration of Chemical Fragment Space; 3.1 Introduction; 3.2 The Enumeration of Chemical Space; 3.2.1 Counting and Sampling Approaches; 3.2.2 Enumeration of the Chemical Universe Database GDB; 3.2.3 GDB Contents; 3.3 Using and Understanding GDB; 3.3.1 Drug Discovery 3.3.2 The MQN System3.3.3 Other Fingerprints; 3.4 Fragments from GDB; 3.4.1 Fragment Replacement; 3.4.2 Shape Diversity of GDB Fragments; 3.4.3 Aromatic Fragments from GDB; 3.5 Conclusions and Outlook; Acknowledgment; References; 4. Ligand Efficiency Metrics and their Use in Fragment Optimizations; 4.1 Introduction; 4.2 Ligand Efficiency; 4.3 Binding Thermodynamics and Efficiency Indices; 4.4 Enthalpic Efficiency Indices; 4.5 Lipophilic Efficiency Indices; 4.6 Application of Efficiency Indices in Fragment-Based Drug Discovery Programs; 4.7 Conclusions; References Part II: Methods and Approaches for Fragment-based Drug Discovery5. Strategies for Fragment Library Design; 5.1 Introduction; 5.2 Aims; 5.3 Progress; 5.3.1 BDDP Fragment Library Design: Maximizing Diversity; 5.3.2 Assessing Three-Dimensionality; 5.3.3 3DFrag Consortium; 5.3.4 Commercial Fragment Space Analysis; 5.3.5 BDDP Fragment Library Design; 5.3.6 Fragment Complexity; 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules; 5.4 Future Plans; 5.5 Summary; 5.6 Key Achievements; References 6. The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery |
| Record Nr. | UNINA-9910137167803321 |
| Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
| Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke |
| Pubbl/distr/stampa | Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 |
| Descrizione fisica | 1 online resource (527 p.) |
| Disciplina | 615.19 |
| Collana | Methods and Principles in Medicinal Chemistry |
| Soggetto topico |
Drug development
Drugs - Design Ligands (Biochemistry) Drug Discovery LIgands |
| ISBN |
3-527-68362-3
3-527-68360-7 3-527-68361-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Fragment-based Drug Discovery: Lessons and Outlook; Contents; Contributors; Preface; A Personal Foreword; Part I: The Concept of Fragment-based Drug Discovery; 1. The Role of Fragment-based Discovery in Lead Finding; 1.1 Introduction; 1.2 What is FBLD?; 1.3 FBLD: Current Practice; 1.3.1 Using Fragments: Conventional Targets; 1.3.2 Using Fragments: Unconventional Targets; 1.4 What do Fragments Bring to Lead Discovery?; 1.5 How did We Get Here?; 1.5.1 Evolution of the Early Ideas and History; 1.5.2 What has Changed Since the First Book was Published in 2006?
1.6 Evolution of the Methods and Their Application Since 20051.6.1 Developments in Fragment Libraries; 1.6.2 Fragment Hit Rate and Druggability; 1.6.3 Developments in Fragment Screening; 1.6.4 Ways of Evolving Fragments; 1.6.5 Integrating Fragments Alongside Other Lead-Finding Strategies; 1.6.6 Fragments Can be Selective; 1.6.7 Fragment Binding Modes; 1.6.8 Fragments, Chemical Space, and Novelty; 1.7 Current Application and Impact; 1.8 Future Opportunities; References; 2. Selecting the Right Targets for Fragment-Based Drug Discovery; 2.1 Introduction 2.2 Properties of Targets and Binding Sites2.3 Assessing Druggability; 2.4 Properties of Ligands and Drugs; 2.5 Case Studies; 2.5.1 Case Study 1: Inhibitors of Apoptosis Proteins (IAPs); 2.5.2 Case Study 2: HCV-NS3; 2.5.3 Case Study 3: PKM2; 2.5.4 Case Study 4: Soluble Adenylate Cyclase; 2.6 Conclusions; References; 3. Enumeration of Chemical Fragment Space; 3.1 Introduction; 3.2 The Enumeration of Chemical Space; 3.2.1 Counting and Sampling Approaches; 3.2.2 Enumeration of the Chemical Universe Database GDB; 3.2.3 GDB Contents; 3.3 Using and Understanding GDB; 3.3.1 Drug Discovery 3.3.2 The MQN System3.3.3 Other Fingerprints; 3.4 Fragments from GDB; 3.4.1 Fragment Replacement; 3.4.2 Shape Diversity of GDB Fragments; 3.4.3 Aromatic Fragments from GDB; 3.5 Conclusions and Outlook; Acknowledgment; References; 4. Ligand Efficiency Metrics and their Use in Fragment Optimizations; 4.1 Introduction; 4.2 Ligand Efficiency; 4.3 Binding Thermodynamics and Efficiency Indices; 4.4 Enthalpic Efficiency Indices; 4.5 Lipophilic Efficiency Indices; 4.6 Application of Efficiency Indices in Fragment-Based Drug Discovery Programs; 4.7 Conclusions; References Part II: Methods and Approaches for Fragment-based Drug Discovery5. Strategies for Fragment Library Design; 5.1 Introduction; 5.2 Aims; 5.3 Progress; 5.3.1 BDDP Fragment Library Design: Maximizing Diversity; 5.3.2 Assessing Three-Dimensionality; 5.3.3 3DFrag Consortium; 5.3.4 Commercial Fragment Space Analysis; 5.3.5 BDDP Fragment Library Design; 5.3.6 Fragment Complexity; 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules; 5.4 Future Plans; 5.5 Summary; 5.6 Key Achievements; References 6. The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery |
| Record Nr. | UNINA-9910676628503321 |
| Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
- Drug Discovery (2)
- Drug development (2)
- Drugs - Design (2)
-
LIgands
(2)
- Ligands (Biochemistry) (2)